Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results

Zosano Pharma (NASDAQ:ZSAN) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray, today announced financial results for the fourth quarter ended December 31, 2017.

As quoted in the press release:

“The fourth quarter continued to see strong execution in bringing M207 to market. We are pleased with the enrollment in our open label, Long-Term Safety Study, and note that we now have 28 sites up and running. We remain confident that we will hit our targets of having 100 subjects on study drug by the end of the first quarter and 250 by the end of the second quarter,” commented John Walker, Chairman and Chief Executive Officer.

Click here to read the full press release.